|
 |
 |
|
 |
 |
|
SEPTEMBER 19 - 20, 2008
Great Debates and Updates in Hematology
Chicago, Illinois
Wyndham Chicago
Chairs
James O. Armitage, MD
University of Nebraska Medical Center
Omaha, Nebraska
Hagop M. Kantarjian, MD
University of Texas
M. D. Anderson Cancer Center
Houston, Texas
Robert Z. Orlowski, MD, PhD
University of Texas
M. D. Anderson Cancer Center
Houston, Texas
James Epstein, MD – Moderator
Imedex, LLC
Alpharetta, Georgia
|
Click
here to register
for this program |
 |
|
I N V
I T A
T I O
N |
 |
|
|
Dear Colleague,
It is our pleasure to invite you to join us for Great Debates & Updates in Hematology, to be held September 19-20, 2008 at the Wyndham Hotel Chicago in Chicago, Illinois. This fall’s conference promises to be an exciting, interactive and educational experience for attendees from all hematology-related disciplines.
Great Debates & Updates in Hematology will cover the broad continuum of hematologic malignancies, from lymphoma to leukemia to myeloma to myeloproliferative disorders, in order to have the broadest appeal to attendees and to provide the most substantial curriculum. This educational agenda will use a combination of didactic presentations, as well as discussions of areas of controversy in hematology in a “debate” format that you will find both enjoyable and educational. Nationally recognized thought leaders will take opposing positions on a topic of interest and provide you with an insightful look at more than one side of a question. The goal is to provide attendees with the most thorough analysis of all currently available and emerging data.
Faculty and audience discussion will focus on how the new data fits into the current community practice of hematology, and will be aimed at facilitating rapid incorporation of important new advances in treatment. Attendees from both academic institutions and community-based settings will be able to identify new areas of research that may not yet be available in community practice.
We hope you will be able to join us for what is sure to be a rewarding experience, as your perspectives and contributions will add immeasurable value to the conference!
Sincerely,
James O. Armitage, MD, Chair
Hagop M. Kantarjian, MD, Chair
Robert Z. Orlowski, MD, PhD, Chair
James Epstein, MD, Moderator
|
|
|
|
S C I
E N T
I F I
C T O P I C S |
|
|
|
Myelodysplastic Syndromes
- Advances in the molecular biology of myelodysplasia
- Should the IPSS be changed to give greater prognostic impact to cytogenetic changes?
- Hypomethylating agents, HDAC inhibitors and their combinations in MDS
Myeloproliferative Disorders
- Emerging clinical data with JAK2 inhibitors
- What is the clinical significance of JAK2 allele burden in PMF?
- Symptom management in myeloproliferative disorders
- How I manage PRV in 2008
Chronic Myeloid Leukemia
- Is CML curable with tyrosine kinase inhibitors?
- T315I: How common, how serious, how treatable?
- When and for whom is stem cell transplant indicated?
Chronic Lymphocytic Leukemia
- Richter’s Syndrome - Risk, Management and Prognosis
- Integrating bendamustine into the treatment algorithm for CLL
- Targeting BCL-2 in CLL
Acute Leukemia
- What is the role of BMT in adult AML
- Evaluating the therapeutic options in elderly AML
- Novel agents in clinical trials for acute leukemia
Hodgkin’s Lymphoma
- What is the best frontline therapy for advanced stage Hodgkin’s lymphoma: ABVD, Stanford V, BEACOPP?
- How much systemic therapy is necessary for early stage Hodgkin’s Lymphoma?
- The role of baseline and interval PET scans in the managmement of early stage Hodgkin’s lymphoma
Non-Hodgkin’s Lymphoma
- Early Stage DLBCL: Chemotherapy vs radio-chemotherapy. Should the XRT decision be based on the results of post-chemotherapy PET scans?
- Novel therapies for follicular lymphoma
- Rituximab-bendamustine or R-CHOP for advanced DLBCL
- Should patients with high risk FL receive anthracycline-based frontline therapy?
- Novel monoclonal antibodies for lymphoma
Multiple Myeloma
- AL amyloidosis: New interest, new options
- Free light chains: Their role in prognosis and monitoring of myleoma
- Clinical revolution in multiple myeloma
|
|
|
|
C O N
T I N
U I N
G M
E D I
C A L
E D U
C A T
I O N |
|
|
Imedex, LLC is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
This activity has been approved for AMA PRA Category 1 CreditTM.
|
|
|
|
W H O
S H O
U L D
A T T
E N D
? |
|
|
|
This educational activity is primarily targeted to academic and community hematologists and oncologists, and secondarily to oncology nurses and other health care professionals interested in the management of patients with hematologic malignancies.
|
|
|
|
O B J
E C T
I V E
S |
|
|
|
After successful completion of this course, attendees should be able to:
- Evaluate and compare current treatment options for newly diagnosed transplant ineligible patients with multiple myeloma
- Compare and contrast the various therapeutic options for patients with relapsed multiple myeloma
- Discuss the pros and cons of stem cell transplantation for patients with multiple myeloma
- Discuss the evolving science of molecular oncology and genomics as it applies to hematologic malignancies
- Describe the emerging novel agents for B-cell and T-cell non-Hodgkins lymphoma
- Discuss therapeutic options for first line therapy of diffuse large B-cell lymphoma
- Evaluate and discuss the emerging role of radioimmunotherapy in follicular lymphoma
- Develop and plan appropriate management strategies for patients with mantle cell lymphoma
- Describe and discuss the role of emerging therapies for both low risk and high risk patients with myelodysplastic syndromes
- Recognize and relate the evolving understanding and emerging therapies for myeloproliferative disorders
- Compare and contrast the various treatment options for chronic myelocytic leukemia
- Evaluate the role of various treatment regimens in the management of chronic lymphocytic leukemia
- Evaluate and discuss the most appropriate treatment options for patients with AML
- Describe and discuss novel emerging therapies for acute myelocytic leukemia
|
|
|
|
|
R E G
I S T
R A T
I O N |
|
|
|
Click
here to register
for this program
REGISTRATION
FEES
Discounted . . . . . . . . . . . . . . .$150
If payment received by September 11, 2008
Full . . . . . . . . . . . . . . . . . . . . $250
If payment received after September 11, 2008
Nurses, Fellows, Residents . . . . $75
To Register: You may register online by September 11, 2008 at www.imedex.com or by calling Imedex at +1 (678) 242 0906. Registration confirmations will be issued before the meeting.
To qualify for special registration fees, registration and full payment must be received by Imedex by the dates specified.
Payment: To pre-register, registration and payment must be received no later than September 11, 2008. Please register onsite after this date. Contact Imedex at +1 (678) 242 0906 or visit our website at www.imedex.com to ensure the course is being held as scheduled and to confirm that the meeting is not full. Registration fees must be remitted by credit card or check. Checks should be payable to Imedex. An attendee is not registered until full payment is received.
Registration Fee Inclusions: Registration fees include admittance to all scientific sessions, conference materials, processing of certificates of attendance or continuing medical education, and all event functions as specified in the program.
Cancellation: For registration fees to be refunded, written notice of cancellation must be received at Imedex no later than September 11, 2008. The amount of registration fees remitted, minus a $50 administrative charge, will be refunded after the conference. Substitutions are accepted with written notification. No refunds will be made if notice is received after September 11, 2008.
Imedex does not accept responsibility for covering travel, accommodation or any other costs incurred by registrants in the rare event that this meeting should be canceled for any reason. Every effort will be made to give reasonable notice in the event of cancellation. The event agenda is subject to change without notice. |
|
|
|
G E N
E R A
L
I N F
O R M
A T I
O N |
|
|
|
CONFERENCE LOCATION AND REGISTRATION
Wyndham Chicago
633 North St. Clair Street
Chicago, Illinois 60611
Tel.: +1 (312) 573 0300
Fax: +1 (312) 274 0164
The Registration and Information Desk will be staffed:
Friday, September 19, 2008 . . . . . 7:00 am – 5:00 pm
Saturday, September 20, 2008 . . . .7:00 am – 5:00 pm
AIR TRAVEL
Contact conference travel agent, Judi Tarpley, Williamsburg Travel, for assistance with your travel
needs. Williamsburg Travel can also accommodate pre- and post-conference extensions.
Tel.: +1 (888) 232 9394
+1 (770) 261 8613
Email: judit@willtrav.com
Imedex is a brand and assumed name used by Imedex, LLC (hereby referred to as Imedex). Imedex is solely responsible for this agenda’s content. Although Imedex attempts to ensure that the information in our program is accurate and timely, matters and opinions discussed and/or presented with respect to clinical matters are those of the discussion participants only, and not necessarily those of Imedex. Moreover, although Imedex attempts to identify and integrate the most qualified medical professionals in our program, TO THE FULLEST EXTENT PERMITTED BY LAW, IMEDEX EXPRESSLY DISCLAIM ALL WARRANTIES, EITHER EXPRESS OR IMPLIED, STATUTORY OR OTHERWISE, INCLUDING BUT NOT LIMITED TO THE IMPLIED WARRANTIES OF MERCHANTABILITY, NON-INFRINGEMENT OF THIRD PARTIES’ RIGHTS, AND FITNESS FOR A PARTICULAR PURPOSE, WITH RESPECT TO THE CONTENT PRESENTED. IMEDEX FURTHER MAKES NO REPRESENTATIONS OR WARRANTIES ABOUT THE ACCURACY, RELIABILITY, COMPLETENESS OR TIMELINESS OF THE CONTENT OR ANY MATERIAL PRESENTED.
In addition, the material presented and related discussions are not intended to be medical advice, and the presentation or discussion of such material is not intended to create and does not establish a physician-patient relationship. Medical advice of any nature should be sought from an individual’s own physician.
Neither Imedex nor any of its subsidiaries or affiliates is affiliated with or formally endorsed by a medical society.
Copyright 2008 Imedex, LLC. All rights reserved. |
|
|
|
H
O T E
L
A C C
O M M
O D A
T I O
N S |
|
|
|
Wyndham Chicago
633 North St. Clair Street
Chicago, Illinois 60611
Tel.: +1 (312) 573 0300
Fax: +1 (312) 274 0164
Website: http://www.wyndham.com/groupeventsnew/orddt_greatdebatesinhemo/main.wnt
The Wyndham Chicago is an oasis of comfort and style in the heart of Chicago’s Magnificent Mile. Just one block off Michigan Avenue in a neighborhood full of world-class restaurants, shopping, museums and galleries. Lake Michigan, the Symphony Center and the Loop financial district are
all nearby.
Settle into a spacious room or suite with a dazzling view of downtown Chicago. Enjoy thoughtful touches like high-speed Internet access and a cordless multi-line phone. Dine at the chic Caliterra Bar & Grille or unwind in the fitness center and indoor pool. Relax with a walk through our vibrant neighborhood - or let the concierge plan a special outing.
For the convenience of attendees, a limited number of rooms have been reserved until August 29, 2008 at a discounted rate of $279 single/double occupancy, plus tax, currently at 15.4%. This rate is not guaranteed outside the conference dates or after August 29, 2008.
To reserve your room please contact the Wyndham Chicago reservations department at +1 (312) 573 0300 or visit the hotel’s website. To receive the group rate, callers must identify themselves as being with the Great Debates in Hematology group. Reservation requests received after August 29, 2008 may not be guaranteed the group rate.
|
|
|
|
O R G
A N I
Z E R |
|
|
|
|
|
©
2008 Imedex®,
LLC. |
|
